News

23andMe Showcases Breakthroughs in Clinical Immuno-oncology

23andMe Showcases Breakthroughs in Clinical Immuno-oncology

23andMe's Innovative Contributions to Immuno-oncology

23andMe Holding Co. (Nasdaq: ME), a prominent player in human genetics and biopharmaceutical innovation, is poised to share exciting developments regarding its clinical immuno-oncology programs, specifically 23ME-00610 and 23ME-01473, at the esteemed ESMO Congress 2024. This significant event will occur from September 13 to September 17 in Barcelona, showcasing the groundbreaking advancements 23andMe is making in cancer treatment.

Exploring New Clinical Data

The company plans to reveal crucial preliminary findings from the renal cancer and TMB-H/MSI-H cohorts in its Phase 1/2a clinical trial for 23ME-00610, which is a cutting-edge anti-CD200R1 antibody. Additionally, 23andMe will provide insights from analyses that evaluate CD200 as an exploratory tissue-based biomarker associated with the effectiveness of 23ME-00610.

Preclinical Findings and Ongoing Studies

Moreover, 23andMe intends to present preclinical data on 23ME-01473, an anti-ULBP6 monoclonal antibody currently in dose escalation studies that commenced in March 2024. These studies are focused on how 23ME-01473 can effectively target soluble ULBP6, a component that plays a role in creating an immunosuppressive environment within tumors.

Clinical Trial Highlights from ASCO

Delving into its recent trial outcomes, 23andMe showcased promising results at the American Society of Clinical Oncology (ASCO) meeting. The monotherapy with 23ME-00610 demonstrated a favorable safety profile, along with early indications of clinical benefits in cohorts facing advanced cancers. Among the notable outcomes was a confirmed partial response in a patient diagnosed with pancreatic neuroendocrine cancer.

Innovative Biomarker Research

The exploration of CD200 is particularly noteworthy, as findings suggest it could act as a potential tissue-based biomarker, thereby enhancing precision in cancer treatment. This represents a significant advancement toward personalized medicine strategies grounded in genetic and immunological evaluations.

Presentation Details at ESMO

Here are the essential details regarding the presentations scheduled for ESMO:

  • Abstract: 1069TiP
    Title: A Phase 1/2a Dose Escalation and Expansion Study of 23ME-01473, an anti-ULBP6/2/5 Antibody for Patients with Advanced Solid Malignancies
    Session Type: Poster Session – Investigational Immunotherapy
    Date and Time: September 14, 9:00-17:00 CEST
  • Abstract: 620P
    Title: Efficacy, Safety and PKPD of 23ME-00610 in Patients with TMB-H and/or MSI-H Cancers: Results from an Expansion Cohort
    Session Type: Poster Session – Developmental Therapeutics
    Date and Time: September 14, 9:00-17:00 CEST
  • Abstract: 153P
    Title: 23ME-01473 Restores Anti-Tumor NK Cell Function Through NKG2D and FcgRIIIa Activation
    Session Type: Poster Session – Biomarkers and Translational Research
    Date and Time: September 15, 9:00-17:00 CEST
  • Abstract: 1706P
    Title: Efficacy, Safety and PKPD of 23ME-00610 in Patients with Advanced Clear-Cell Renal Cell Carcinoma
    Session Type: Poster Session – Renal Cancer
    Date and Time: September 15, 9:00-17:00 CEST
  • Abstract: 150P
    Title: Phase 1/2a Trial of CD200R1 Inhibitor 23ME-00610; Exploratory Analyses of Biomarkers
    Session Type: Poster Session – Biomarkers and Translational Research
    Date and Time: September 15, 9:00-17:00 CEST

Understanding the Innovations

23ME-00610 is engineered to inhibit the interaction between CD200R1 and CD200, targeting the CD200–CD200R1 axis, which is a vital immunological checkpoint that regulates immune tolerance. By targeting this pathway, it may enhance the ability of immune cells to combat cancer more effectively.

In contrast, 23ME-01473 aims to restore anti-tumor immune responses through Natural Killer (NK) and T cells by targeting the ULBP6 ligands that cancer cells often shed to avoid detection. This mechanism bolsters the immune response against tumors, potentially transforming the field of cancer immunotherapy.

About 23andMe

23andMe is leading the way in integrating genetic data into healthcare solutions and developing biopharmaceutical products that promise a healthier future for everyone. They harness genetic insights gathered from millions of participants to investigate and validate potential treatments based on genetic predispositions.

Frequently Asked Questions

What new trials will 23andMe present at ESMO Congress 2024?

23andMe will present trials related to its anti-CD200R1 antibody, 23ME-00610, and the anti-ULBP6 monoclonal antibody, 23ME-01473.

What is 23ME-00610?

23ME-00610 is a first-in-class monoclonal antibody targeting CD200R1, aimed at enhancing immune responses against cancer.

What is the significance of CD200 in cancer treatment?

CD200 serves as an immunological checkpoint; blocking its pathway could restore immune function in cancer patients.

How does 23ME-01473 function?

23ME-01473 targets soluble ULBP6 to encourage NK and T cell recognition of cancer cells, restoring anti-tumor immunity.

What role does 23andMe's genetic database play?

The genetic database enables 23andMe to discover drug targets by correlating genetic variants with immune response and cancer risk.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Knob-and-Tube Wiring: A Hidden Hazard Unveiled

Updated Category News Views 76

Unlocking the Mysteries of Knob-and-Tube Wiring Ever wondered if the wiring in your charming hundred-year-old home might be a ticking time bomb? Welcome to the world of knob-and-tube wiring. This blast from the past might just be hiding in those walls and could spell trouble. The History and Hazards of Knob-and-Tube This wiring system dates back to the 1880s, sticking...

Continue Reading
SKYWORTH Solar's Solavita: Energizing Global Microgrids

Updated Category News Views 237

Aiming for Global Reach with Solavita Usually, when a company flings a new brand into the arena, you're looking at a whole bunch of promises and probably a fat folder of paperwork you don't want to read. But when SKYWORTH Solar dishes out Solavita as its new ace in the smart microgrid game, you reckon there's a bit of serious starch in the collar. Harnessing Worldwide...

Continue Reading
Extend Your Water Heater's Life with Anode Care

Updated Category News Views 148

Small Component, Big Impact: The Anode Rod Picture this: You’ve got a trusty water heater keeping your showers steamy, but lurking inside is a villain called rust. Enter the unsung hero—the anode rod. It might not be glamorous, but this little piece of metal works overtime to save your tank from a watery grave. Tim Fessler and Dave Super, seasoned plumbing hotshots...

Continue Reading
Dutch Bros Pours Holiday Cheer with New Festive Menu

Updated Category News Views 32

New Festive Offerings from Dutch Bros Kicking off the holiday season with a splash of vibrant flavors, Dutch Bros is shaking up the menu with some fresh, festive entries. Two new drink concoctions hit the stage alongside a themed delectable treat, and for those traditionalists, perennial favorites make a triumphant return. Dutch Bros Expands Its Vibrant Lineup It's not...

Continue Reading
Afghanistan Claims Hong Kong Sixes in Thrilling Run Chase

Updated Category News Views 34

Afghanistan's Dazzling Triumph Brace ourselves, because what just unfolded in the Hong Kong Sixes 2026 is nothing short of spectacular. Afghanistan's cricket team penned a brand-new chapter in the game's history by overcoming Australia in a pulsating final to capture their maiden Hong Kong Sixes title. Imagine this: chasing a formidable target of 116, they wrapped up the...

Continue Reading
Decoding LRV: Smart Paint Choices for Your Home

Updated Category News Views 91

Unraveling the Secrets of LRV Nobody thought analyzing paint meant diving into light reflectance values (LRV), but that's precisely where we're headed today. Painting a room seems simple until you realize your color choice might turn your bright haven into a cave or vice versa. Thanks to some insights from Wendy Anguiano in HelloNation, let's dig into this technical...

Continue Reading
UBCF Strikes Big in Times Square with New Billboards

Updated Category News Views 219

From the Shadows to the Spotlight Ever seen someone step up to the plate and knock it out of the park? That's what the United Breast Cancer Foundation (UBCF) is doing by plastering their mission right across Times Square. Talk about grabbing the bull by the horns, eh? With not one, but two billboards now gracing one of the globe's most iconic public spaces, they've...

Continue Reading
TESSAN and Jamie Leibert's Daring Alpine Documentary Launch

Updated Category News Views 36

Steps Beyond the Obvious Adventure Launching headlong into the unknown—literally and figuratively—is what the documentary Jump Into The Unknown captures. TESSAN and Jamie Leibert have peeled back the curtain on adventure, showing us that it’s not just about the destination, but every twist, turn, and recalibrated step in between. The Backstory Behind Every Jump...

Continue Reading
Termite Swarmers: Essential Clues and Action Steps

Updated Category News Views 116

Understanding the Intrusive Nature of Termite Swarmers When it comes to creepy crawlies wreaking havoc on your beloved abode, termites are the stealthy troublemakers you need to keep an eye out for. Just because you catch a glimpse of them doesn't mean the damage is obvious or minimal. Spotting the Culprits: Termites vs. Ants Identifying what you're up against is the...

Continue Reading
Navigating Underinsured Motorist Coverage Woes

Updated Category News Views 62

When the Rubber Hits the Road: Coverage Gaps Ever been in a fender bender and found out the other driver’s insurance barely covers a dent, let alone a serious crash? Believe me, it's no picnic. Chuck Clark from HelloNation digs into this with a deep dive on underinsured motorist coverage, or UIM for short. It's an eye-opener—especially if you're assuming your auto...

Continue Reading

Top 5 Most Recently Viewed Articles

AutoCanada Reports Q3 Performance and Future Outlook

Updated Category News Views 230

AutoCanada Q3 Results Overview AutoCanada Inc. (TSX: ACQ), a major multi-location automobile dealership group in North America, recently unveiled its financial performance for the third quarter, showing total revenue generated from continuing operations of $1,201.5 million. This represents a decline compared to the $1,412.5 million recorded in the same period last year,...

Continue Reading
FuelCell Energy Secures Significant Financing for Korean Project

Updated Category News Views 173

FuelCell Energy's Remarkable Financing Achievement FuelCell Energy, Inc. (NASDAQ: FCEL) has recently reached a pivotal milestone by securing $25 million in financing through the Export-Import Bank of the United States (EXIM). This significant funding showcases EXIM's ongoing commitment to supporting innovative projects and bolsters FuelCell Energy's objectives to provide...

Continue Reading
Nikkei 225 Declines as Market Faces Mixed Results from Sectors

Updated Category News Views 206

Market Overview of Japan's Stock Performance The Japanese stock market closed lower, reflecting challenges faced by several major sectors. The Nikkei 225 index, a benchmark for the Tokyo Stock Exchange, experienced a decline of 0.83%, as various sectors struggled to keep pace amidst evolving market conditions. Key Sectors Impacting the Nikkei 225 Several sectors...

Continue Reading
MixAid Shines at the 2025 Inspired Home Show Showcase

Updated Category News Views 453

MixAid Showcases Innovation at the Inspired Home Show MixAid, an innovative kitchen gadget designed to enhance the functionality of stand mixer bowls, recently made its debut at a significant event known as the Inspired Home Show New Product Showcase 2025. Highlights from the Inspired Home Show This annual event in the home and housewares industry is deeply rooted in...

Continue Reading
Exploring the Growth Potential of Geospatial Analytics Market

Updated Category News Views 133

Geospatial Analytics Market Overview The global geospatial analytics market is experiencing significant growth and is set to become a multibillion-dollar industry. Recent reports indicate that the market, which was valued at approximately $85.5 billion, is expected to reach $220.2 billion by 2033, reflecting a compound annual growth rate (CAGR) of 9.6% from 2024 to 2033....

Continue Reading